Cargando…

Vascular progenitor cell senescence in patients with Marfan syndrome

Vascular progenitor cells (VPCs) present in the adventitia of the vessel wall play a critical role in the regulation of vascular repair following injury. This study aimed to assess the function of VPCs isolated from patients with Marfan syndrome (MFS). VPCs were isolated from control and MFS donors...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Haiwei, Yu, Baoqi, Liu, Zipeng, Ye, Gen, You, Wei, Hong, Yimei, Lian, Qizhou, Zhang, Yuelin, Li, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6533473/
https://www.ncbi.nlm.nih.gov/pubmed/30920150
http://dx.doi.org/10.1111/jcmm.14301
_version_ 1783421211284340736
author He, Haiwei
Yu, Baoqi
Liu, Zipeng
Ye, Gen
You, Wei
Hong, Yimei
Lian, Qizhou
Zhang, Yuelin
Li, Xin
author_facet He, Haiwei
Yu, Baoqi
Liu, Zipeng
Ye, Gen
You, Wei
Hong, Yimei
Lian, Qizhou
Zhang, Yuelin
Li, Xin
author_sort He, Haiwei
collection PubMed
description Vascular progenitor cells (VPCs) present in the adventitia of the vessel wall play a critical role in the regulation of vascular repair following injury. This study aimed to assess the function of VPCs isolated from patients with Marfan syndrome (MFS). VPCs were isolated from control and MFS donors and characterized. Compared with control‐VPCs, MFS‐VPCs exhibited cellular senescence as demonstrated by increased cell size, higher SA‐β‐gal activity and elevated levels of p53 and p21. RNA sequencing showed that several cellular process‐related pathways including cell cycle and cellular senescence were significantly enriched in MFP‐VPCs. Notably, the expression level of TGF‐β1 was much higher in MFS‐VPCs than control‐VPCs. Treatment of control‐VPCs with TGF‐β1 significantly enhanced mitochondrial reactive oxidative species (ROS) and induced cellular senescence whereas inhibition of ROS reversed these effects. MFS‐VPCs displayed increased mitochondrial fusion and decreased mitochondrial fission. Treatment of control‐VPCs with TGF‐β1 increased mitochondrial fusion and reduced mitochondrial fission. Nonetheless, treatment of mitofusin2 (Mfn2)‐siRNA inhibited TGF‐β1‐induced mitochondrial fusion and cellular senescence. Furthermore, TGF‐β1‐induced mitochondrial fusion was mediated by the AMPK signalling pathway. Our study shows that TGF‐β1 induces VPC senescence in patients with MFS by mediating mitochondrial dynamics via the AMPK signalling pathway.
format Online
Article
Text
id pubmed-6533473
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-65334732019-06-01 Vascular progenitor cell senescence in patients with Marfan syndrome He, Haiwei Yu, Baoqi Liu, Zipeng Ye, Gen You, Wei Hong, Yimei Lian, Qizhou Zhang, Yuelin Li, Xin J Cell Mol Med Original Articles Vascular progenitor cells (VPCs) present in the adventitia of the vessel wall play a critical role in the regulation of vascular repair following injury. This study aimed to assess the function of VPCs isolated from patients with Marfan syndrome (MFS). VPCs were isolated from control and MFS donors and characterized. Compared with control‐VPCs, MFS‐VPCs exhibited cellular senescence as demonstrated by increased cell size, higher SA‐β‐gal activity and elevated levels of p53 and p21. RNA sequencing showed that several cellular process‐related pathways including cell cycle and cellular senescence were significantly enriched in MFP‐VPCs. Notably, the expression level of TGF‐β1 was much higher in MFS‐VPCs than control‐VPCs. Treatment of control‐VPCs with TGF‐β1 significantly enhanced mitochondrial reactive oxidative species (ROS) and induced cellular senescence whereas inhibition of ROS reversed these effects. MFS‐VPCs displayed increased mitochondrial fusion and decreased mitochondrial fission. Treatment of control‐VPCs with TGF‐β1 increased mitochondrial fusion and reduced mitochondrial fission. Nonetheless, treatment of mitofusin2 (Mfn2)‐siRNA inhibited TGF‐β1‐induced mitochondrial fusion and cellular senescence. Furthermore, TGF‐β1‐induced mitochondrial fusion was mediated by the AMPK signalling pathway. Our study shows that TGF‐β1 induces VPC senescence in patients with MFS by mediating mitochondrial dynamics via the AMPK signalling pathway. John Wiley and Sons Inc. 2019-03-28 2019-06 /pmc/articles/PMC6533473/ /pubmed/30920150 http://dx.doi.org/10.1111/jcmm.14301 Text en © 2019 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
He, Haiwei
Yu, Baoqi
Liu, Zipeng
Ye, Gen
You, Wei
Hong, Yimei
Lian, Qizhou
Zhang, Yuelin
Li, Xin
Vascular progenitor cell senescence in patients with Marfan syndrome
title Vascular progenitor cell senescence in patients with Marfan syndrome
title_full Vascular progenitor cell senescence in patients with Marfan syndrome
title_fullStr Vascular progenitor cell senescence in patients with Marfan syndrome
title_full_unstemmed Vascular progenitor cell senescence in patients with Marfan syndrome
title_short Vascular progenitor cell senescence in patients with Marfan syndrome
title_sort vascular progenitor cell senescence in patients with marfan syndrome
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6533473/
https://www.ncbi.nlm.nih.gov/pubmed/30920150
http://dx.doi.org/10.1111/jcmm.14301
work_keys_str_mv AT hehaiwei vascularprogenitorcellsenescenceinpatientswithmarfansyndrome
AT yubaoqi vascularprogenitorcellsenescenceinpatientswithmarfansyndrome
AT liuzipeng vascularprogenitorcellsenescenceinpatientswithmarfansyndrome
AT yegen vascularprogenitorcellsenescenceinpatientswithmarfansyndrome
AT youwei vascularprogenitorcellsenescenceinpatientswithmarfansyndrome
AT hongyimei vascularprogenitorcellsenescenceinpatientswithmarfansyndrome
AT lianqizhou vascularprogenitorcellsenescenceinpatientswithmarfansyndrome
AT zhangyuelin vascularprogenitorcellsenescenceinpatientswithmarfansyndrome
AT lixin vascularprogenitorcellsenescenceinpatientswithmarfansyndrome